Merger results in Quatris Health

| | Health Exec | Precision Medicine

On January 1, Alliance Healthcare Solutions and Final Support merged to form Quatris Health, the largest privately held company authorized to sell and support GE Healthcare’s Centricity Practice Solution. The new company builds on Alliance and Final Support’s combined 25 years of experience implementing, supporting and hosting the practice management and EMR software products.

While both Alliance and Final Support offered cloud data hosting services, the new company looks to develop this sideline into an essential part of the business. As of its formation, Quatris Health is responsible for the storage and backup of more than 18 million patient health records.

Over the next few months, the company will focus on strengthening its relationship with GE Healthcare.

Quatris Health will maintain offices in Bedford, Texas; Rocklin, Calif.; Fort Wayne, Ind.; and Kailua, Hawaii. Further information can be found on the company’s website, Quatris.com.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.